Zenith Capital (Zenith Capital) Stock Based Compensation : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Stock Based Compensation?

Zenith Capital's Stock Based Compensation for the three months ended in . 20 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Zenith Capital Stock Based Compensation Historical Data

The historical data trend for Zenith Capital's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Stock Based Compensation Chart

Zenith Capital Annual Data

Trend

Stock Based Compensation

Zenith Capital Quarterly Data

Stock Based Compensation

Zenith Capital Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zenith Capital Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines